v3.26.1
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 01, 2024
Nov. 15, 2023
Aug. 31, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Commitments and Contingencies [Line Items]              
Accrued amount       $ 750,000      
Monthly payments       $ 5,000      
Gross sales revenues percentage       10.00%      
Common stock market value       $ 179,286      
Revenue derived term     10 years        
Research and development expenses       9,300 $ 74,234    
Dr. Marvis S. Hausman [Member]              
Commitments and Contingencies [Line Items]              
Monthly payments     $ 245,712        
Issuance of common stock shares (in Shares)     750,000        
Common stock market value     $ 100,800        
Dr. Marvin Hausman [Member]              
Commitments and Contingencies [Line Items]              
Royalty percentage     5.00%        
Nova Mentis Life Sciences Corp. [Member]              
Commitments and Contingencies [Line Items]              
Research and development expenses           $ 100,800  
CFO Agreement [Member]              
Commitments and Contingencies [Line Items]              
Monthly payments to agreement   $ 8,750          
Funds raises       750,000      
Accrued amount       750,000      
Accrued fees payable       77,802 $ 98,058    
Aggregate commitment amount       8,750      
Chief Science Officer Agreement [Member] | Hausman [Member]              
Commitments and Contingencies [Line Items]              
Monthly payments $ 8,750            
Employment Agreement [Member]              
Commitments and Contingencies [Line Items]              
Funds raises       750,000      
Accrued fees payable       219,500     $ 205,000
Aggregate commitment amount       $ 8,750